Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 3/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | YAP1 | P46937 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047524 | 1.00 | KLK7 (0.40) | KLK7KLK5CTSSPPARAGPR119 | |
| SCHEMBL3390164 | 1.00 | KLK7 (0.40) | KLK7KLK5CTSSPPARAGPR119 | |
| SCHEMBL1051333 | 0.89 | PSMB11 (0.35) | KLK7KLK5HTR2C | |
| SCHEMBL3389163 | 0.89 | PSMB11 (0.35) | KLK7KLK5HTR2C | |
| SCHEMBL3389166 | 0.89 | PSMB11 (0.35) | KLK7KLK5HTR2C | |
| SCHEMBL16545983 | 0.84 | SPHK1 (0.41) | KLK7KLK5CTSSGPR119SPHK1 | |
| SCHEMBL17819587 | 0.84 | SPHK1 (0.41) | KLK7KLK5CTSSGPR119SPHK1 | |
| SCHEMBL1836162 | 0.82 | SPHK1 (0.42) | KLK7KLK5CTSSPPARAGPR119 | |
| SCHEMBL1836163 | 0.82 | SPHK1 (0.42) | KLK7KLK5CTSSPPARAGPR119 | |
| SCHEMBL3389152 | 0.80 | SPHK1 (0.43) | SPHK1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756037-B1 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-7786307-B2 | suchas N-(4(S)-amino-5(S)-hydroxy-2(S)-isopropyl-6-piperidin-1-ylhexyl)-2-(3-methoxypropoxy)benzamide dihydrochloride, used for the treatment of hypertension, cardiovasculr disorders, complications owing to diabetes, vision deffects, hyperaldosteronism, states of anxiety and cognitive disorders | NOVARTIS AG (CH) | 2010-08-31 | — | — | US | disclosed |
| US-20070155743-A1 | Amino alcohol derivatives and their activity as renin inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-05 | — | — | US | disclosed |
| EP-1756037-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005070871-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155743-A1 | Amino alcohol derivatives and their activity as renin inhibitors | REN, AGTR1, AGTR2 | KLK7 1903/4885KLK5 1219/4885CTSS 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.